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Centralized scientific
communities are less likely to
generate replicable results
Abstract Concerns have been expressed about the robustness of experimental findings in several
areas of science, but these matters have not been evaluated at scale. Here we identify a large sample
of published drug-gene interaction claims curated in the Comparative Toxicogenomics Database (for
example, benzo(a)pyrene decreases expression of SLC22A3) and evaluate these claims by connecting
them with high-throughput experiments from the LINCS L1000 program. Our sample included 60,159
supporting findings and 4253 opposing findings about 51,292 drug-gene interaction claims in 3363
scientific articles. We show that claims reported in a single paper replicate 19.0% (95% confidence
interval [CI], 16.9–21.2%) more frequently than expected, while claims reported in multiple papers
replicate 45.5% (95% CI, 21.8–74.2%) more frequently than expected. We also analyze the subsample
of interactions with two or more published findings (2493 claims; 6272 supporting findings; 339
opposing findings; 1282 research articles), and show that centralized scientific communities, which
use similar methods and involve shared authors who contribute to many articles, propagate less
replicable claims than decentralized communities, which use more diverse methods and contain more
independent teams. Our findings suggest how policies that foster decentralized collaboration will
increase the robustness of scientific findings in biomedical research.
DOI: https://doi.org/10.7554/eLife.43094.001
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Introduction
Concerns over reliability (Ioannidis, 2005) and
reproducibility (Prinz et al., 2011; Begley and
Ellis, 2012) in biomedical science call into ques-
tion the cumulative process of building on prior
published results. In a publication environment
that rewards novel findings over verifications
(Nosek et al., 2015; Alberts et al., 2015), the
replicability of research claims that biomedical
scientists assemble into biological models, drug
development trials, and treatment regimes
remains unknown (Begley and Ellis, 2012;
Yildirim et al., 2007). Exact replications of bio-
medical research (Errington et al., 2014) occur
only on small scales due to prohibitive expense
and limited professional incentive.
Replication failures are typically attributed to
systemic bias in a publication system that favors
positive results (Ioannidis, 2005). This
incentivizes questionable research choices such
as p-hacking (Head et al., 2015;
Simonsohn et al., 2014), ‘flexible’ data analysis
(Simmons et al., 2011), low statistical power
(Dumas-Mallet et al., 2017), selective reporting
(the ‘file drawer problem’) (Rosenthal, 1979),
and confirmation bias (Nuzzo, 2015). These
questionable choices, combined with incomplete
reporting of statistical methods and data
(Nosek et al., 2015), contribute to the publica-
tion of false results that are unlikely to replicate
in future experiments (Simmons et al., 2011).
Here we investigate the community that coa-
lesces around a drug-gene interaction claim. We
hypothesize that a decentralized community of
largely independent, non-overlapping teams,
which draws from a diverse pool of prior publi-
cations, using distinct methods under varying
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produce robust results. Conversely, we expect
that a centralized community involving repeated
collaborations and using a narrow range of
methods, knowledge from prior publications
and experimental conditions is likely to produce
less robust results. Unfortunately, repeated col-
laboration (Hicks and Katz, 1996;
Guimerà et al., 2005), growing teams
(Wuchty et al., 2007), star scientists (Mer-
ton, 1968; Azoulay et al., 2014), expensive
shared equipment, and common citations
(Evans, 2008; Simkin and Roychowdhury,
2005; White et al., 2004) are defining charac-
teristics of the biomedical research enterprise
today (Hicks and Katz, 1996; Hand, 2010).
Prior simulations have suggested that inde-
pendent labs are less prone to peer pressure
than a densely connected network of scientists,
in which misleading early results can propagate
more easily (Zollman, 2007; Payette, 2012).
Related research on the ‘wisdom of crowds’
(Lorenz et al., 2011) and the exploration-exploi-
tation trade-off (Lazer and Friedman, 2007)
also found densely connected networks to be
inefficient, and suggested that networks of semi-
isolated subgroups would lead to an improve-
ment in collective performance (Fang et al.,
2010). A more recent experiment demonstrates
that decentralized networks, rather than inde-
pendence, may most improve collective
performance. In estimation tasks completed by
networks of individuals, it was found that the
dominance of central individuals in networks
tended to bias the collective estimation process
and decrease the average accuracy of group
estimates (Becker et al., 2017).
A separate body of literature attributes
robustness of scientific findings to diverse meth-
ods (Kaelin, 2017; Wimsatt, 2012) used to cor-
roborate them or distinct theories used to
motivate them. A classic example is Jean Perrin’s
use of multiple experimental techniques and
theories to precisely determine Avogadro’s
number (Salmon, 1984). Nevertheless, there has
been no comprehensive evaluation of the rela-
tionship between the way scientific communities
are networked and the robustness and replica-
bility of published findings. Moreover, when
empirical data on scientific collaboration have
been used (Guimerà et al., 2005), the outcomes
of collective performance have typically been
measured indirectly (e.g., via article or journal
citations). Similarly, literature on research
reliability has focused on methodological fea-
tures rather than the way scientific communities
are networked. Moreover, there has been rela-
tively little research of this nature in the field of
biomedical science.
Here we demonstrate a strategy for evaluat-
ing the replication likelihood for tens of thou-
sands of drug-gene interaction claims. This
strategy builds on the synergy of two advances.
First, databases of empirical claims curated from
the scientific literature in certain subject areas
such as molecular toxicology and biochemistry
(Davis et al., 2017) can be linked to databases
of scientific articles such as MEDLINE and the
Web of Science to systematically analyze fea-
tures that characterize the provenance of a sci-
entific claim (Evans and Foster, 2011) such as
authors, affiliations, and the number of experi-
ments for and against. Second, data from high-
throughput experiments (Subramanian et al.,
2017) performed by robots allow researchers to
estimate the replication likelihood for many pub-
lished claims. Here we report the results of anal-
yses performed on claims identified by
comparing the Comparative Toxicogenomics
Database (CTD; Davis et al., 2017) and the
LINCS L1000 experiment (Subramanian et al.,
2017; see Figure 1 and Materials and methods).
The CTD had recorded over 1.26 million
drug-gene interaction (DGI) claims published in
journals as of June 7, 2016, with each claim
being a ‘triple’ of a drug, a gene and an interac-
tion effect. We selected interaction effects in
which a drug either ‘increases expression’ or
‘decreases expression’ of an mRNA in human tis-
sues. This resulted in a sample of 239,713 DGI
claims curated from 11,754 scientific articles.
The LINCS L1000 experiment generated 1.3 mil-
lion gene expression profiles from 42,080 pertur-
bagens across a range of different cell lines,
time points and dosage levels. Each profile con-
sisted of a drug, a gene (mRNA) and a z-score.
The LINCS L1000 experiment consolidated mul-
tiple expression profiles to generate a moder-
ated z-score for each experimental condition,
and we combined these into a single combined
z-score for each drug and gene (mRNA). We
matched these triples from the LINCS L1000
experiments to triples in the CTD, and found
51,292 drug-gene interactions at the intersec-
tion, corresponding to 60,159 supportive find-
ings and 4253 opposing findings from the
literature, annotated from 3363 scientific articles
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(see Supplementary file 1). We use this sample
to estimate how the probability of claim replica-
tion depends on support in the literature, social
independence, methodological independence,
knowledge independence, scientist centraliza-
tion, journal prominence, and experimental vari-
ability (see Materials and methods).
Our high-throughput replication strategy
evaluates the replicability of a broad scientific
claim rather than the reproducibility of any sin-
gle experiment contributing to that claim. (The
evaluation of an individual experiment requires
the original experimental protocol to be
repeated in the new experiment
[Errington et al., 2014].) Nevertheless, collec-
tive agreement across many published findings
provides evidence for a robust claim – that is, a
claim that withstands changes in the technique
used (Wimsatt, 2012; Nosek and Errington,
2017; Kaelin, 2017), the scientists doing the
research and the experimental setting. Such
claims form a solid foundation for further
research and, potentially clinical trials based on
the claim.
Results
Distribution and agreement of
experiments
We observe a long-tailed distribution of pub-
lished findings in support of a given DGI claim
(Figure 1A). Most claims are supported by find-
ings in one (89%) or two (8%) articles, while few
appear in many articles. There is wide consensus
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Figure 1. Alignment of drug-gene interaction (DGI) claims reported in the literature with DGI claims from high-
throughput experiments. (A) Our analysis of 51,292 DGI claims (see Supplementary file 1) in the literature
revealed 60,159 supporting findings (green) and 4253 opposing findings (pink) in aggregate. These DGI claims co-
occurred in both the CTD publication dataset and the LINCS L1000 exerimental dataset. Most claims (45,624) were
supported by just one published finding, 4127 claims were supported by two published findings, and the
remaining 1541 claims were supported by three or more published findings. Some claims (3154) were both
supported and opposed by the published findings, meaning that in addition to the supporting finding(s), there is
one or more increase/decrease interactions in the CTD dataset that propose the opposite effect: 2563 claims were
opposed by one, 376 by two, and 215 by three or more published findings. Please note that both axes in the main
graph are logarithmic. (B) We calculated experimental effect sizes with combined z-scores for the 51,292 DGI
triples in the LINCS L1000 dataset. This graph plots the probability (y-axis) versus absolute value of the combined
z-score for all triples (blue line) and those that are significant at the 0.05 level (salmon line). Significant in this
context means that the drug-gene effect is observed across a range of experiment conditions; the method used to
determine significance is described in Materials and methods.
DOI: https://doi.org/10.7554/eLife.43094.002
The following figure supplements are available for figure 1:
Figure supplement 1. Publications that share authors are more likely to agree about the direction of a drug-gene
interaction than publications with distinct authors, computed among pairs of papers reporting claims in the sub-
corpus of 2493 claims.
DOI: https://doi.org/10.7554/eLife.43094.003
Figure supplement 2. Estimates of probability density functions for variables of interest in our corpus using a
normal kernel function.
DOI: https://doi.org/10.7554/eLife.43094.004
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findings (93%) agree on the direction of DGI
claims. Among the 11% of claims supported by
two or more published findings, the agreement
increases to 94%. In contrast, only 41% (21,181/
51,292) of the DGI effect-sizes in LINCS L1000
generalize across experimental conditions
(Figure 1B). Although those two quantities –
agreement among published findings and gen-
eralizability of LINCS L1000 effect sizes – are not
directly comparable as they utilize different
measurements, the overwhelming agreement
observed in the literature compared to the
LINCS L1000 data suggests that the literature
may influence the selection and interpretation of
experimental results by scientists through confir-
mation bias. One consequence of this is that
experimental results that contradict preexisting
knowledge are ‘filed away’ rather than submit-
ted to journals (Rosenthal, 1979).
Further, we find that consensus in the bio-
medical literature is strongly and positively asso-
ciated with connections between papers arising
from overlapping authors. A pair of findings
about a DGI claim reported in papers with some
of the same authors are significantly more likely
to agree (0.989, 2486 of 2514 overlapping pairs
of papers) than findings reported in papers by
socially independent teams (0.889, 18,527 of
20,846 non-overlapping pairs of papers), with a
mean difference of 0.1001 (95% CI, 0.094–0.106,
P <.0001, 100,000 bootstrap iterations; Fig-
ure 1—figure supplement 1).
Replication rates
For a given set of claims it is possible to esti-
mate a random or baseline replication rate
RRrand and an observed replication rate RRobs
(along with 95% confidence limits for both) using
the approach outlined in ‘Measuring relative
replication increase’ (see Methods and materi-
als). For our sample we estimate RRobs to be
0.556 (95% CI, 0.553–0.558, N = 51,292 claims)
and RRrand to be 0.503 (95% CI, 0.498–0.506,
N = 51,292 claims): this corresponds to a per
centage relative replication increase (RRI =
((RRobs – RRrand)/RRrand)  100%) of 10.6% (95%
CI, 9.3%–11.8%). Figure 2D shows that, as
expected, DGIs that generalize across experi-
mental conditions in LINCS L1000 are more
likely to replicate published DGI claims (RRobs =
0.604, 95% CI, 0.597–0.610, n = 21,181 claims)
than DGIs that do not generalize (RRobs = 0.522,
95% CI, 0.516–0.528, n = 30,111 claims). Indeed,
the replication rate for the latter group is only
marginally higher than RRrand for this group
(RRrand = 0.501, 95% CI, 0.496–
0.507, n = 30,111 claims). Encouragingly, this
suggests that some disagreement within the lit-
erature is attributable to experimental and bio-
logical variation in the experiments performed
by different scientists. In the subsequent analy-
sis, we consider generalized LINCS L1000 DGIs
because only those can serve to evaluate the
replicability of published claims.
Collective correction in science
A central concern is whether the replication
problem applies only to novel and rare claims or
if it also afflicts widely supported results, as
recently hypothesized (Nissen et al., 2016;
McElreath and Smaldino, 2015). To examine
this question, we integrated collective findings
using a binomial Bayesian model (Gelman et al.,
2013) with a uniform prior that accommodates
skewed distributions (Davidson-Pilon, 2015) like
that of findings per claim we observed. The
model allocates higher probability to scientific
claims unanimously supported in a large number
of articles and lower probability to infrequent
and disputed claims (Figure 2A). The resulting
posterior distributions of support were used to
categorize DGI claims into five classes of sup-
port: Very High, High, Moderate, Low support,
and Not Supported (see Figure 2B and Materi-
als and methods).
Figure 2E shows that claims with Very High
support in the biomedical literature
(RRI = 45.5%; 95% CI, 21.8–74.2%) with an aver-
age of 6.9 papers confirming the claim, and
claims with High support (RRI = 34.5%; 20.2–
50.3%) with an average of 3.3 confirming
papers, are substantially more likely to replicate
in high-throughput experiments than those with
Low and Moderate support (RRI = 19.0%; 16.9–
21.2% and 16.2%; 9.8–22.9%, respectively). The
replication of claims with Low and Moderate
support is consistent with reproducibility esti-
mates reported in the literature, ranging from
11% (N = 67; Begley and Ellis, 2012) to 25%
(N = 53; Prinz et al., 2011). Claims with Very
High and High support replicate at a much
higher rate, whereas Not Supported claims are
significantly less likely to replicate than random
(RRI =  28.9%;  61.9%–16.7%). They are also
associated with greater experimental variability
(Figure 2F), confirming that collective disagree-
ments among findings truthfully signal experi-
mentally unstable interactions peculiar to
specific contexts and unlikely to replicate.
Logistic models adjusting for experimental
variability confirm the positive relationship
between scientific support in the literature Lsupt
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Drug-gene interaction claimSupport Oppose
Figure 2. Estimates of claim replication as a function of the probability of support in the literature and generalizability across high-throughput
experiments. (A) Posterior distributions of probability of support in the biomedical literature for a sample of seven DGI claims for which there are at
least two findings (supporting and/or opposing). Note that the top three claims receive only supporting findings in the literature, whereas the fourth
and fifth claims are opposites (so papers that support the fourth claim oppose the fifth claim, and vice versa), and likewise for the sixth and seventh
claims. We obtained model estimates for each claim by performing 10,000 Markov chain Monte Carlo (MCMC) sampling iterations (see Materials and
methods). For each claim, we summarize the probability of support (dashed vertical line) using the lower bound on the one-sided 95% posterior
credible interval: this value ranges from 0.84 for a claim that is supported by 16 findings and opposed by no findings, to 0.03 for a claim that is
supported by one finding and opposed by 10 findings. (B) DGI claims in the literature can be categorized into one of five classes of support (Very High;
High; Moderate; Low; Not Supported) on the basis of distributions like those in panel A; the number of claims included in each class is shown in
brackets. (C) Number of DGI claims that are significant (second row) and not significant (third row) at the 0.05 level in the LINCS L1000 dataset for the
whole corpus (second column) and for each of the five classes of support in the literature (columns 3–7). (D) Observed replication rates (RRobs) and
expected replication rates (RRrand) for claims that are significant and non-significant in the LINCS L1000 dataset for the whole corpus (left) and for each
of the five classes of support in the literature. (E) The relative replication increase rate (RRI ¼ 100 RRobs RRrand
RRrand
) for claims that are significant in the LINCS
L1000 dataset (left) and for each of the five classes of support in the literature. (F) Variability (coefficient of variation) in the LINCS L1000 dataset across
cell lines, durations and dosages for claims that are significant in this dataset (left) and for each of the five classes of support in the literature. Statistical
significance and error bars were determined by bootstrapping (see Materials and methods). All error bars represent 95% CI.
DOI: https://doi.org/10.7554/eLife.43094.005
The following figure supplements are available for figure 2:
Figure supplement 1. Replication increases with claim’s probability of support in the literature.
DOI: https://doi.org/10.7554/eLife.43094.007
Figure 2 continued on next page
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and the probability of replication success (Fig-
ure 2—figure supplement 1). These results sug-
gest that findings reported in a single
biomedical article are likely fallible. Viewed as a
complex system of converging and diverging
findings, however, biomedicine exhibits collec-
tive correction.
We note that the process of collective correc-
tion applies to a small subset of claims as the
majority of claims (89%) in our corpus are only
reported in a single paper. Multiple factors
could account for why a large proportion of
claims in the corpus are not reported in repeat
experiments. The lower replication rate of sin-
gle-study claims indicates that many of those
novel claims were likely obtained by chance.
Even if tested further, they are less likely to pro-
duce positive results compared to multiple-stud-
ied claims, and thus more likely to be filed away
than submitted to a journal. This interpretation
is supported by our finding that single-study
claims in our corpus (ie, claims in the Low sup-
port class) have a RRobs of only 0.601, while the
first published studies about multiple-studied
claims that eventually achieve High or Very High
support have a RRobs of 0.720.
Networked scientific communities and
replicability
Independent and decentralized sources of evi-
dence should increase claim robustness. We
examine the impact of social and technical
dependencies on the replication of biomedical
claims by fitting logistic regression models to
predict replication success against our network
dependency measures for each claim. We per-
formed this analysis using subsamples of DGI
claims that simultaneously: 1) received support
from multiple papers in the literature (i.e., claims
with Moderate and above support in the litera-
ture), thereby converging on an effect direction;
and 2) generalized across conditions in LINCS
L1000. The resulting subsample consists of 2493
claims, associated with 6272 supporting and 339
opposing findings from 1282 research articles
(see Supplementary file 2). Despite the smaller
size of this subsample, our analysis represents
the largest biomedical replication of its kind to
date. We restrict our analysis of dependencies
to a subsample of published DGI claims
supported by multiple papers because single-
paper claims cannot, by definition, exhibit net-
work dependencies or centralization. By examin-
ing only interactions having significant
agreement within both the literature and LINCS
L1000, we can directly examine the effect of
social, methodological, and knowledge depen-
dencies on the replicability of published claims
in high-throughput experiments (see Figure 3
and Figure 4).
Figure 4A shows that the odds ratios (OR) of
replication increase substantially with support in
the literature Lsupt (OR 23.20, 95% CI, 9.08–
59.3), social independence Sind (OR 6.31, 95%
CI, 4.07–9.79), methodological independence
Mind (OR 6.30, 95% CI, 3.44–11.53), and knowl-
edge independence K ind (OR 5.53; 95% CI,
2.58–11.84). Consistent with this pattern, claim
replication decreases sharply with centralization
C (OR 0.36, 95% CI, 0.27–0.48). Our estimates
indicate that claim robustness, defined here as
repeated instances of confirmatory decentral-
ized evidence, increases replication success (see
also Figure 4—figure supplement 1). When all
predictors are modeled simultaneously
(Figure 4A), centralization and support in the lit-
erature largely account for all of the others. This
suggests that centralized and extensive biomedi-
cal collaboration is associated with use of the
same biomedical research techniques and atten-
tion to the same prior research (see Figure 3—
figure supplement 1).
Social dependencies could impact the com-
position of researchers studying a claim by dis-
couraging researchers outside the dense
communities of researchers who initially lay claim
to it from pursuing or reporting their findings, as
suggested in previous research (Azoulay et al.,
2015). Focusing on High and Very High support
claims with some degree of centralization
(n = 295), we found that claims originally
reported and subsequently confirmed by papers
with overlapping authors (n = 117) resulted in
much more centralized communities (mean
C = 0.6164; 95% CI, 0.5925–0.6402) compared
to claims reported and subsequently confirmed
by papers with independent authors (n = 178;
mean C = 0.4004; 95% CI, 0.3765–0.4242; two-
way ANOVA test with unbalanced design.) This
exploratory result suggests that claims
Figure 2 continued
Figure supplement 2. Description of claim types in the whole corpus of 51,292 claims.
DOI: https://doi.org/10.7554/eLife.43094.006
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exhibiting social dependencies very early in their
development likely receive limited attention and
reportage from researchers outside the commu-
nities that originated them.
An alternative explanation for replication suc-
cess is the biological tendency for some
DGI claims to generalize across conditions and
so replicate in future experiments. Figure 4A
shows that experimental variability has a nega-
tive, marginally significant effect on replication,
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Figure 3. Exemplary networks comprising social, methodological, and references dependences and centralization patterns in scientific communities.
(A) Multilayer networks for four of the claims shown in Figure 2A. The nodes in each layer are scientific papers. Pairs of papers are connected by an
unweighted edge in the top layer if they agree on the effect direction, and by a weighted edge in the other layers if there is an overlap of authors
(second layer), methodologies (third layer) or references to prior publications (fourth layer): the thickness of the weighted edges is proportional to the
overlap (Jaccard coefficient; JC); for clarity, we only plot edges above the mean JC value in the third layer. Dashed red lines in the top layer separate
supporting and opposing findings. Each layer is associated with a score: support in the literature Lsupt, social independence Sind, methodological
independence Mind, and knowledge independence Kind (see ‘Network dependencies and centralization’ in Methods and materials). Figures plotted with
Pymnet (Kivela€, 2017). (B) Bipartite network with edges connecting authors (rectangles) to the papers they published (circles) for the 10 papers that
support the claim shown in the fourth panel of Figure 3A. A small group of investigators author most of these papers, while most investigators author
only one paper, making this a centralized network. The Gini coefficient (see Materials and methods) for this network is 28.3%. (C) Bipartite network for
the six papers that support the claim shown in the third panel of Figure 3A. Here all investigators author relatively comparable numbers of papers: this
decentralized network has a Gini coefficient of 12.4%. (D, E) Lorenz curves for the examples shown in B and C.
DOI: https://doi.org/10.7554/eLife.43094.008
The following figure supplements are available for figure 3:
Figure supplement 1. Pearson correlation coefficients between network indices.
DOI: https://doi.org/10.7554/eLife.43094.009
Figure supplement 2. Papers and pairs of papers are differentiated by the number of findings they report (in the sub-corpus of 2493 claims).
DOI: https://doi.org/10.7554/eLife.43094.010
Danchev et al. eLife 2019;8:e43094. DOI: https://doi.org/10.7554/eLife.43094 7 of 18
Feature article Meta-Research Centralized scientific communities are less likely to generate replicable results
decentralized communities are much more infor-
mative predictors of replication success.
Our combined model also accounts for jour-
nal prominence J, which we measure with journal
eigenfactor (Bergstrom et al., 2008), a score
that credits journals receiving many citations
from highly cited journals. Claim replication
increases with journal prominence (Figure 4A
and Figure 4—figure supplement 1), but prom-
inent journals are responsible for only a tiny frac-
tion of all claims. This warrants our evaluation
strategy and the practice of extracting and
archiving findings from a wide range of journals
(Davis et al., 2017).
Figure 4B shows that by accounting for bio-
medical support and decentralization, we can
identify claims with high predicted probability of
replication. Claims supported by many
publications have about 45% higher predicted
probability to replicate when investigated by
decentralized versus centralized communities.
Even if a DGI claim garners wide support, if it is
studied exclusively by a centralized scientific
community, the claim has a predicted probability
of replication that is similar to that for a claim
reported in a single paper. It is unlikely that such
a claim will clear a clinical trial or enter medical
practice (see Figure 4—figure supplement 2).
This suggests that collective correction in sci-
ence can be undermined when one or several
scientists exercise disproportionate influence on
research across multiple investigations of a
claim. Likewise, claims robust to many, socially
independent investigations have 55% higher
predicted probability of replication than those
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Figure 4. Predictors of replication success. (A) Odds ratios derived from logistic regression models with claim replication as the response variable and
seven predictors modeled independently (disconnected colored dots; n = 2493) and simultaneously (connected grey triangles; n = 2491). Predictors are
rescaled xi min xð Þmax xð Þ min xð Þ for comparability. P-values are adjusted for multiple comparisons using the Benjamini–Hochberg (Benjamini and Hochberg, 1995)
procedure. (B–C) Contour plots showing that the predicted probability of claim replication (derived from logistic regression models with interaction
terms, see also Figure 4—figure supplements 2,3) increases with decentralization and support in the literature (B), and with social independence and
support in the literature (C), after adjusting for variability in LINCS L1000.
DOI: https://doi.org/10.7554/eLife.43094.011
The following figure supplements are available for figure 4:
Figure supplement 1. Predictors of replication success.
DOI: https://doi.org/10.7554/eLife.43094.012
Figure supplement 2. Claims reported by centralized communities less likely replicate.
DOI: https://doi.org/10.7554/eLife.43094.014
Figure supplement 3. Claims reported by multiple socially independent teams more likely replicate.
DOI: https://doi.org/10.7554/eLife.43094.015
Figure supplement 4. Estimates of probability density functions for our variables on the sub-corpus of claims with determined direction of the drug-
gene effect in CTD and LINCS L1000.
DOI: https://doi.org/10.7554/eLife.43094.013
Figure supplement 5. Support in the literature and decentralization of scientific communities remain strong and significant predictors of claim
replication success after we account for multicollinearity.
DOI: https://doi.org/10.7554/eLife.43094.016
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(Figure 4C and Figure 4—figure supplement
3). All models adjust for experimental variability
in the LINCS L1000 data. Results are robust to
outliers and multicollinearity (see Appendix 1).
Discussion
This paper repurposes high-throughput experi-
ments to evaluate the replicability of tens of
thousands of DGI claims from the biomedical lit-
erature. It provides evidence that research repli-
cability is associated with the way scientific
collaborations are networked, after adjusting for
variability in high-throughput experiments and
the methodology of published studies. Central-
ized, overlapping communities with shared
methodologies and exposure to the same prior
knowledge are supported by extensive collabo-
ration (Hicks and Katz, 1996; Hand, 2010),
ubiquitous communication technologies, a
reward system that places a premium on pro-
ductivity, and cumulative advantage processes
that create central, star biomedical scientists
(Azoulay et al., 2014). Our results indicate that
such communities are associated with scientific
findings of lower replicability. Decentralized,
sparsely connected communities explore diverse
research methodologies and prior knowledge
(Figure 3—figure supplement 1) and are more
likely to generate replicable findings.
Our work addresses widely shared concerns
about the robustness of research results in bio-
medicine. Recent work (Nissen et al., 2016;
McElreath and Smaldino, 2015) submitted that
reliability issues uniformly impact scientific find-
ings, afflicting even widely accepted ‘facts’. Nis-
sen et al. reason that even if many studies
converge on the same finding, this may not
increase our confidence because the same sys-
tematic biases – publication bias in particular –
that made the original finding false are also
likely to affect subsequent findings, resulting in a
canonization of ‘false facts’ (Nissen et al.,
2016). Our analysis identifies conditions under
which such an argument holds, namely for
research claims studied by centralized, overlap-
ping collaborations. In the absence of social
independence, replicability is low and the likeli-
hood of a claim being revised or withdrawn is
virtually non-existent as authors and methods
reinforce agreement with themselves. Both dis-
agreement and replication increase when teams
from a decentralized or sparsely connected com-
munity provide separate confirming evidence for
a claim. Our findings allay science policy con-
cerns over a universal ‘replication crisis’ and
identify conditions – decentralized and novel col-
laborations – that facilitate collective conver-
gence on replicable findings in biomedical
science.
Our findings highlight the importance of sci-
ence policies that promote decentralized and
non-repeated collaborations. We acknowledge
that certain ‘big science’ initiatives (Hand, 2010),
such as the human genome project
(International Human Genome Sequencing
Consortium, 2001), involve large international
consortiums that require a degree of repeated
collaboration and centralization by design. It is
also the case that the current organization of sci-
ence incentivizes repeated collaborations
(Guimerà et al., 2005; Lungeanu and Contrac-
tor, 2015; Hilton and Cooke, 2015), including
centralized communities revolving around star
scientists (Azoulay et al., 2014) or prestigious
and well-endowed institutes. By reducing infor-
mation and coordination costs, repeated collab-
orations are more productive than new ones
(Hilton and Cooke, 2015). Consequently, proj-
ects that involve prior collaborators are more
likely to be funded (Lungeanu et al., 2014) and
successfully completed (Cummings and Kiesler,
2008). Such positive feedback, however, can
lead to the lock-in of rigid collaborative clusters,
which produce voluminous scientific output with
diminished value for the wider biomedical field.
Science policies supporting biomedicine should
account for the trade-off between increased pro-
ductivity and diminished reliability.
Our choice of repurposing the LINCS L1000
data to estimate the replication likelihood of
published claims places importance on unfiltered
high-throughput experiments for our results. We
note, however, that our approach does not rely
on the LINCS L1000 data being completely free
from error. Rather, we argue that the LINCS
L1000 data are: i) produced with methods repre-
sentative of DGI research; ii) free from social,
prior knowledge and narrow methodological
dependencies associated with the sequential
publication of findings by communities of
researchers. In this way, our manuscript attempts
to elucidate biases introduced by the social, cul-
tural and methodological structure of science to
noisy experimental data. From this perspective,
LINCS L1000 experiments must remain unfil-
tered by the publication system and the expect-
ations of any particular scientific community. In
the current state of the biomedical literature,
where most reported results are confirmatory,
scalable approaches for identifying uncertain
claims are in short supply. Experimental data
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such as the LINCS L1000 provides an informed
approach to evaluate published claims.
This paper demonstrates an approach to
evaluate the replicability of potentially vast num-
bers of published biomedical claims simulta-
neously. With the proliferation of high-
throughput experimental platforms and
improvements in cross-platform reproducibility
(Haibe-Kains et al., 2013), the approach we
report here could be further refined and
extended to a continuous replication system
(Goodman et al., 2016) that revises scientific
results in light of new experimental evidence,
increasing the credibility and robustness of bio-
medical knowledge.
Materials and methods
High throughput claim replication strategy
We examined a corpus of 51,292 scientific claims
about drug-gene interactions in human systems.
We compiled the corpus by using claims about
directed drug-gene interactions (DGIs) curated
from biomedical publications in the Comparative
Toxicogenomics Database (CTD) (Davis et al.,
2017). Each scientific claim is a triple of drug,
gene, and interaction effect. For comparability
with high-throughput experiments, we selected
interaction effects in which a drug ‘increases
expression’ or ‘decreases expression’ of an
mRNA in humans (effect magnitudes were not
recorded), amounting to 239,713 DGI claims
curated from 11,754 scientific articles. The CTD
provides PubMed IDs of articles in which the
finding is reported, which enabled examination
of article content (e.g., methods) and metadata
(e.g., authors, citations).
To estimate replication likelihood, we map
our corpus of DGI claims to high-throughput
experimental data from the NIH LINCS L1000
program, which was performed at the Broad
Institute of MIT and Harvard. This program gen-
erated 1.3M gene expression profiles from
42,080 chemical and genetic perturbagens
across cell lines, time points, and dosage levels
(Subramanian et al., 2017). We used profiles
induced by chemical perturbagens, amounting
to 19,811 small molecule compounds (including
FDA approved drugs). The LINCS L1000 data
have been reported to be highly reproducible
(Subramanian et al., 2017) compared to drug
screen data generated via RNA sequencing,
instances of which have been found to exhibit
inconsistencies across platforms (Haibe-
Kains et al., 2013).
The LINCS L1000 team consolidated multiple
expression profiles or replicates into signatures
corresponding to moderated
(Subramanian et al., 2017) z-scores (Level five
data in LINCS L1000). Each signature and corre-
sponding moderated z-score is a representation
of gene responses to drug perturbations under
a particular cell line, dosage, and duration. We
combined moderated z-scores for each DGI
using a bootstrapped modification of Stouffer’s






p , where zi is a moderated z-score
and k is the number of moderated z-scores for
the DGI. We bootstrapped (10,000 iterations)
each sample of moderated z-scores per DGI to
estimate confidence intervals. The samples vary
across DGIs as a function of the number of cell
lines, dosages, and durations under which the
DGI was tested (the mean and median of mod-
erated z-scores per DGI in our corpus are 143.8
and 49, respectively).
The above procedure generates triples of (i)
drug, (ii) gene (mRNA), and (iii) combined
z-score indicating experimental effect size and
direction. We matched DGI triples from the
LINCS L1000 experiments to DGI triples in CTD,
and found 51,292 DGIs at the intersection, cor-
responding to 60,159 supportive and 4253
opposing findings from the literature, annotated
from 3363 scientific articles (Appendix 1 details
data sources). To verify that published findings
have been obtained independently from the
LINCS L1000 high-throughput data, a search in
PubMed was performed using the search terms
LINCS L1000 and L1000. The search identified




We used the confidence intervals for the com-
bined z-scores we estimated via bootstrapping
for each of the 51,292 DGIs to differentiate gen-
eralized from context-specific interactions in
LINCS L1000. We classified DGIs as ’generalized’
those significant at the 0.05 level (i.e., the corre-
sponding 95% confidence intervals do not con-
tain the null value of 0; see Figure 2C and 2D).
For generalized/significant DGIs, we further
examine robustness to experimental conditions
(Kaelin, 2017; Goodman et al., 2016;
Van Bavel et al., 2016) by measuring variability
of each interaction in LINCS L1000 across cell
lines, dosages, and durations using the coeffi-
cient of variation (CV). For a set of z-scores
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about a DGI in LINCS L1000, CV z is defined as
the ratio of the standard deviation to the abso-
lute value of the mean CV z ¼ szabsðzÞ. CV z is a nor-
malized measure of variability that allows us to
make comparisons across DGIs.
Bayesian model of scientific support
Claims about DGIs receive different proportions
of supporting and opposing published findings.
To estimate the probability of support or confir-
mation in the literature Lsupt for each DGI claim,
we design a simple Bayesian model
(Gelman et al., 2013; Davidson-Pilon, 2015;
Kruschke, 2014). We assume that the prior dis-
tribution of q is uniform on the interval [0,1]: qi
~Uniform(min = 0, max = 1). Further, we assume
that the number of supporting published find-
ings g in n findings about that claim is drawn
from a binomial distribution, p(g |q) ~ Bin(g |n, q).
We approximated the posterior density of q for
each drug-gene claim by performing 10,000
Markov chain Monte Carlo (MCMC)
sampling iterations (2,500 burn-in iterations) for
each drug-gene claim using the Metropolis–
Hastings MCMC sampler implemented in the
PyMC package (version 2.3.6) for Python. To
improve convergence, we approximate the max-
imum posterior (MAP) before running the
MCMC sampler (Davidson-Pilon, 2015).
We used the posterior distributions from our
Bayesian model of support to categorize DGI
claims into classes. For each claim, we estimated
the overlap between the posterior credible inter-
vals (PCI) and the null value of m = 0.5
(Figure 2B): Very High support claims
(95%PCI exceeds m) yield agreement from multi-
ple papers (~7 papers on average), amounting
to 325 claims supported by 2241 findings, but
only opposed by 21; High support claims
(80%PCI exceeds m) yield agreement from 3
papers on average, comprising 1083 claims, sup-
ported by 3525 and opposed by 42 findings;
Moderate support claims (68%PCI exceeds m)
yield agreement from 2 papers on
average, comprising 3743 claims, supported
by 7557 and opposed by 38 findings; Low sup-
port claims (68%PCI contains m) are overwhelm-
ingly supported by a single finding or opposed
by virtually the same number of findings that
support them such that the direction of the
effect is undetermined, comprising 46,064
claims, supported by 46,735 and opposed
by 3668 findings. Not Supported claims
(68%PCI is smaller than m) generate lower sup-
port than expected as a greater number of
papers reported findings in the opposite direc-
tion, comprising only 77 claims, supported by
101 and opposed by 484 findings (Figure 2—
figure supplement 2).
Measuring relative replication increase
A DGI is replicated, R ¼ 1; if the direction of the
effect size (i.e., positive or negative combined
z-score) in LINCS L1000 matches the direction of
the effect (i.e., increase or decrease) claimed in
literature, and R ¼ 0; otherwise. For the entire
corpus and for selected subsets of the corpus,
we created replication vectors [1, 0] and calcu-
lated observed replication rates RRobs by divid-
ing the number of replicated claims by the total
number of claims. We then bootstrapped
(100,000 iterations) the replication vectors to
estimate the 95% percentile confidence intervals
of RRobs (Figure 2D). We empirically estimated
the baseline or random replication rate RRrand
(the proportion of random matches in which
LINCS L1000 effects matched the direction of
the effects reported in the literature) for the
entire corpus and for various subsets of the cor-
pus by iteratively matching published DGI claims
to randomized combined z-scores in LINCS
L1000 (100,000 random permutations). We
then used the resulting permutation distribu-
tions to determine the 95% confidence intervals
of RRrand. The empirical baseline model corrects
for unbalanced data, which would occur if more
claims of a certain direction, either ‘increasing’
or ‘decreasing’, are present in both literature
and high-throughput experiments. The percent-
age relative replication increase RRI is defined
as: RRI ¼ 100 RRobs   RRrand=RRrandð Þð .
Network dependencies and centralization
We represent network dependencies for each
claim as a multilayer network (Kivela et al.,
2014) M ¼ ðVM;EM; LÞ (Figure 3A). In each net-
work layer L, nodes V are biomedical papers
and edges E between pairs of papers represent
either a binary relationship of agreement ðL1Þ or
the amount of overlap between the authors ðL2Þ,
methodologies ðL3Þ, and references to prior
publications ðL4Þ in the two papers. We quantify
the amount of overlap between research papers
using the Jaccard coefficient (JC). For any attri-
bute – i.e., authors, methods, or references – Ai
and Aj, JC is the size of intersection divided by
the size of the union: JCðAi;AjÞ ¼
Ai \Ajj j
Aij jþ Ajj j  Ai \Ajj j.
The resulting quantity represents the edge
weight between a pair of articles in the
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respective network layers of shared authors L2ð Þ,
methods L3ð Þ, and references L4ð Þ. Each drug-
gene claim constitutes an undirected, multilayer
network of papers connected via such weighted
edges across layers (see Figure 3A).
We define an independence score IND as the
proportion of maximum possible edges
(Wasserman and Faust, 1994) in a network layer




W is the sum over all weighted edges in a claim’s
respective layer of shared authors, methods, or
references. Our independence scores can be
viewed as the probability that any two randomly
chosen findings about a claim are obtained by dis-
connected sets of authors (social independence
S ind), methods (methodological independence
Mind), and references (knowledge independence
Kind), respectively. The independence scores
approach one when most papers with findings in
support of a claim share no common authors,
methods, and references, and 0 when all papers
share all of their authors, methods, and referen-
ces, respectively (see Appendix 1).
To quantify the centralization of research
communities C for each claim, we employed the
Gini coefficient. The Gini coefficient is used to
measure the heterogeneity of distributions in
social and information networks (Kunegis and
Preusse, 2012). The coefficient ranges between
0 and 1. In the context of a bipartite author-arti-
cle network (Figure 3B–C), the coefficient
approaches 0 when all investigators author equal
numbers of articles about a claim and increases
to 0.3 and above (depending on the number of
articles), when one investigator authors all
articles and all others author only one. The Gini
coefficient can be also represented as a percent-
age ranging from 0 to 100, as in Figure 2D–E.
While other measures of network centralization
are available (e.g., Freeman’s centralization
[Freeman, 1978]), the Gini coefficient, and the
Lorenz curve on which it is based, is indepen-
dent from the underlying degree distribution,
making it suitable for comparisons among net-
works with different size and mean degree
(Kunegis and Preusse, 2012; Badham, 2013).
Replication prediction models
We fit univariate, multivariate, and interaction
logistic regression models to estimate odds
ratios, relative risk, and predicted probabilities
of claim replication as a function of support in
the literature Lsupt, social independence Sind,
methodological independence Mind, knowledge
independence Kind, centralization C, journal
prominence J, and experimental variability CV .
First, for exploratory purposes, we model each
variable independently (see Figure 4A, Fig-
ure 4—figure supplement 1, and
Supplementary file 3). Second, we model our
variables simultaneously (see Figure 4A, Fig-
ure 4—figure supplement 1, and
Supplementary file 4):
logitP R¼ 1ð Þ ¼ b0 þb1 Lsuptþb2 Sindþ
b3 Mindþb4 Kindþb5 Cþb6 Jþb7 CV
Third, we estimate two interaction models to
examine the effect of support in the literature on
replication success as a function of social inde-
pendence and centralization, respectively (see
Figure 4B–C and Figure 4—figure supplements
2,3):
logitP R¼ 1ð Þ ¼ b0 þb1Lsupt Sind þb2CV
b0 þb1 Lsupt Cþb2 CV
To estimate and visualize the logistic regres-
sion models, we used the glm() function, speci-
fying binomial distribution and the canonical
logit link function, and the packages effects
(Fox, 2003), sjPlot (Lüdecke, 2019), and
ggplot2 (Wickham, 2016), all in R.
Data availability
The data and computer code associated with
this analysis are available on the Open Science
Framework at https://osf.io/xmvda/.
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High throughput drug-gene interactions
We used the Library of Integrated Network-based Cellular Signatures (LINCS) Phase I L1000
data set (Subramanian et al., 2017) to estimate claim replication. The data set measures the
expression of 978 landmark genes treated with wide range of perturbagens across cell lines,
time points, and dosage levels (concentration), resulting in approximately 1.3M profiles. The
experimental profiles are aggregated to 473,647 signatures, as represented in Level five data
we used to perform our analysis. The landmark genes are subsequently used to infer gene
expressions for the remaining genes in the human genome. In addition to the 978 landmark
genes, we consider 9196 for which the LINCS L1000 project estimated to be well inferred,
resulting in 10,174 Best INferred Genes (BING) in total. With respect to perturbagen types, we
used the set of small-molecule compounds (19,811 compounds), which includes a subset of
approximately 1,300 FDA-approved drugs. We accessed the data file
GSE70138_Broad_LINCS_Level5_COMPZ_n118050  12328_2017-03-06.gctx.gz and
metadata from the GEO depository at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE70138.
Published drug-gene interactions
We analysed curated data about published interactions between chemicals/drugs and genes/
mRNAs released by the Comparative Toxicogenomics Database (CTD) (Davis et al., 2017) on
June 7 2016. (The current CTD data release is available here: http://ctdbase.org/downloads/).
To align triples of drug, gene, and interaction effect in CTD to corresponding triples in the
experimental signatures from LINCS L1000, we performed the following procedures. First, we
selected drug-gene interactions about Homo sapiens, comprising approximately 40% of the
CTD data. Second, CTD reports the form of the gene (e.g., mRNA, protein) that is implicated,
and we selected only mRNA as LINCS L1000 measures gene expression at the mRNA level.
Third, we mapped chemical names and Entrez gene IDs in the CTD to perturbagen names and
Entrez gene IDs in LINCS L1000. Fourth, to ensure comparability to the LINCS L1000
signatures, we selected drug-gene interactions with a single interaction effect, either
’decreases expression’ or ’increases expression’, defining the direction of the effect that
chemical/drug manifests on a gene/mRNA. Note that we do not consider complex interactions
with multiple, nested effects in our analysis. Likewise, interactions for which the direction of
the effect is not specified, such as ’affects binding’, are not considered. The resulting corpus
at the intersection of LINCS L1000 and CTD comprises 51,292 drug-gene claim combinations
of 605 unique drugs and 9123 unique genes, annotated from 3363 scientific articles.
Variables of claim provenance extracted from article metadata and
content
Social independence and centralization
We used the MEDLINE/PubMed database to extract the set of authors for each paper. To
measure the overlap between two sets of authors, we need individual author identifiers.
Author name disambiguation is a common problem in research on scientific knowledge
production. We used the individual identifiers based on author last name and initials. We note
that because we assessed authors separately for each claim, our conservative matching
procedure is very unlikely to produce false positive author linkages, and so our author co-
paper network should be considered a lower bound for author co-paper density. For the sub-
corpus of 2493 claims, sourced from 1282 papers, we estimated a mean of 6.4 authors per
paper and a mean of 23.5 authors per scientific community defined here as the total number
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of authors that have published papers reporting a drug-gene claim. For the set of papers
supporting a claim, we used JC to measure the overlap between the authors in the various
pairs of papers in the set, and then used our independence score to calculate the social
independence Sind of the claim. Further, we applied the Gini coefficient to the bipartite author-
article network for each claim to compute community centralization.
Methodological independence
We compiled a controlled vocabulary of 3074 terms (incl. synonyms) concerning methods,
techniques, and experimental apparatus used in biomedical research using ontologies of
biomedical investigations (Bandrowski et al., 2016) and statistics (Gonzalez-Beltran et al.,
2016). We then used the RESTful API Web Service of Europe PMC to query the methods
sections from 4.4 million full text articles and extracted, on aggregate, 13,095 terms for 488
articles (38%). In parallel, for all 1282 articles that share a drug-gene claim, we applied fuzzy
matching against our vocabulary using the difflib module in Python and extracted 12,135
terms from abstracts available in MEDLINE/PubMed. We combined outputs from the two
search procedures. Then, for the set of papers supporting a claim, we again used JC to
measure the overlap between methods in the various pairs of papers in the set, and then used
our independence score to calculate the methodological independence Mind of the claim.
Prior knowledge independence
To examine whether a pair of publications is exposed to similar or dissimilar prior information,
we use the notion of bibliographic coupling (Kessler, 1963), i.e., the number of citations any
two papers share. To compute bibliographic coupling, we used the Web of Science citation
data. Out of 1282 papers sharing a drug-gene claim with at least one other paper, we
mapped 1234 PubMed IDs to Web of Science IDs and performed bibliographic coupling on
this subset using Python modules Tethne (Peirson and Erick, 2017) and NetworkX
(Hagberg et al., 2008). 880 of our 1234 papers were coupled bibliographically by at least one
paper. Consistent with the procedure we applied to measure shared authors and methods, we
used JC to measure the overlap between the citations in the various pairs of papers in the set,
and then used our independence score to calculate the prior knowledge independence Kind of
the claim.
Journal prominence
To measure journal prominence, we employed the journal eigenfactor score (Bergstrom et al.,
2008). The eigenfactor score acts like a recursively weighted degree index by rating journals
highly that receive citations from journals that are themselves highly cited. Journal eigenfactor
scores were computed using the Web of Science database. We obtained journal eigenfactor
scores for 3162 papers (94% of all 3363 papers in our corpus) published in 656 journals
between 1995 and 2016. For the sub-corpus of 1282 papers with shared drug-gene claims, we
recovered 1212 papers or 95% published in 496 journals. For each claim, we computed mean
journal eigenfactor scores by averaging over the eigenfactor score of all journals that
published a paper reporting findings in support of the claim. The distribution of mean journal
eigenfactor scores (i.e., journal prominence) per claim is highly skewed (Figure 1—figure
supplement 2 and Figure 4—figure supplement 4), indicating that claims receive
overwhelmingly support from findings published in low and medium ranked journals. This
highlights the value of archiving findings across a wide range of journals, as do CTD and other
scientific database projects, which makes possible our large-scale evaluation of scientific
output.
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Robustness analysis
Some of our variables are correlated (e.g., methodological independence and prior
knowledge independence; see Figure 3—figure supplement 1), which is to be expected as
they capture related dimensions of scientific knowledge production. We performed a
multicollinearity test using the variance inflation factor (VIF). The variance inflation factors vary
from low for variability in LINCS L1000 (VIF = 1.015), journal prominence (VIF = 1.135), and
support in literature (VIF = 1.534) to moderate for centralization (VIF = 3.162), methodological
independence (VIF = 3.752), prior knowledge independence (VIF = 4.681), and social
independence (VIF = 4.900). We observe no predictor with high variance inflation factor, i.e.,
VIF 10. We removed the two variables with the highest VIF >4 and refit our logistic
regression model. In the refitted model, both support in the literature and decentralization of
scientific communities remain strong and significant predictors of replication success
(Figure 4—figure supplement 5). Further, we verified that the effects of support from the
literature and community centralization on claim replication success are not dominated by
outliers. Recall the long-tailed distribution of findings per claim, with few claims receiving
support from many published findings (Figure 1A). We removed claims supported by 10 or
more findings, amounting to 26 claims supported by 426 findings and found that support from
the literature (OR 34.785; 95% CI, 12.518–96.662, p = 1.00e-11) and community centralization
(OR 0.335; 95% CI, 0.249–0.451, p = 5.57e-13) remain strong and significant predictors of
replication success, after adjusting for biological and experimental variability in LINCS L1000
(OR 0.726; 95% CI, 0.429–1.232; p = 0.236). Similarly, the distribution of findings per paper
and per pair of papers is heterogeneous (Figure 3—figure supplement 2). We removed the
largest set of 796 drug-gene claims reported by a pair of papers and found that the effect of
support from the literature (OR 19.512; 95% CI, 7.193–52.929, p = 5.37e-09) and centralization
(OR 0.432; 95% CI, 0.287–0.65, p = 5.71e-05) holds and is not explained by variability in LINCS
L1000 (OR 0.574; 95% CI, 0.279–1.181; p = 0.131).
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